Towards an advanced cell-based in vitro glioma model system.

AIMS Genetics Pub Date : 2018-03-19 eCollection Date: 2018-01-01 DOI:10.3934/genet.2018.2.91
Valeriia Mikhailova, Valeriia Gulaia, Vladlena Tiasto, Stanislav Rybtsov, Margarita Yatsunskaya, Alexander Kagansky
{"title":"Towards an advanced cell-based <i>in vitro</i> glioma model system.","authors":"Valeriia Mikhailova,&nbsp;Valeriia Gulaia,&nbsp;Vladlena Tiasto,&nbsp;Stanislav Rybtsov,&nbsp;Margarita Yatsunskaya,&nbsp;Alexander Kagansky","doi":"10.3934/genet.2018.2.91","DOIUrl":null,"url":null,"abstract":"<p><p>The modulation of tumor growth and development <i>in vitro</i> has always been one of the key factors in the research of the malignant transformation, including gliomas, prevalent and most deadly cancers of the brain. Indeed, cellular and molecular biology research employing <i>in vitro</i> model cell-based systems have great potential to advance both the mechanistic understanding and the treatment of human glial tumors, as it facilitates not only the understanding of glioma biology and its regulatory mechanisms Additionally they promise to afford the screening of the putative anti-tumor agents and alternative treatment approaches in a personalized manner, i.e. by virtue of using the patient-derived tumor material for such tests. However, in order to become reliable and representative, glioma model systems need to move towards including most inherent cancer features such as local hypoxia, specific genetic aberrations, native tumor microenvironment, and the three-dimensional extracellular matrix. This review starts with a brief introduction on the general epidemiological and molecular characteristics of gliomas followed by an overview of the cell-based <i>in vitro</i> models currently used in glioma research. As a conclusion, we suggest approaches to move to innovative cell-based <i>in vitro</i> glioma models. We consider that main criteria for selecting these approaches should include the adequate resemblance to the key <i>in vivo</i> characteristics, robustness, cost-effectiveness and ease to use, as well as the amenability to high throughput handling to allow the standardized drug screening.</p>","PeriodicalId":43477,"journal":{"name":"AIMS Genetics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698577/pdf/","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIMS Genetics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3934/genet.2018.2.91","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 12

Abstract

The modulation of tumor growth and development in vitro has always been one of the key factors in the research of the malignant transformation, including gliomas, prevalent and most deadly cancers of the brain. Indeed, cellular and molecular biology research employing in vitro model cell-based systems have great potential to advance both the mechanistic understanding and the treatment of human glial tumors, as it facilitates not only the understanding of glioma biology and its regulatory mechanisms Additionally they promise to afford the screening of the putative anti-tumor agents and alternative treatment approaches in a personalized manner, i.e. by virtue of using the patient-derived tumor material for such tests. However, in order to become reliable and representative, glioma model systems need to move towards including most inherent cancer features such as local hypoxia, specific genetic aberrations, native tumor microenvironment, and the three-dimensional extracellular matrix. This review starts with a brief introduction on the general epidemiological and molecular characteristics of gliomas followed by an overview of the cell-based in vitro models currently used in glioma research. As a conclusion, we suggest approaches to move to innovative cell-based in vitro glioma models. We consider that main criteria for selecting these approaches should include the adequate resemblance to the key in vivo characteristics, robustness, cost-effectiveness and ease to use, as well as the amenability to high throughput handling to allow the standardized drug screening.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
建立一种先进的基于细胞的体外神经胶质瘤模型系统。
肿瘤体外生长发育的调节一直是恶性转化研究的关键因素之一,包括胶质瘤、常见和最致命的脑癌。事实上,采用体外模型细胞系统的细胞和分子生物学研究在促进对人类神经胶质瘤的机制理解和治疗方面具有巨大潜力,因为它不仅有助于理解神经胶质瘤生物学及其调控机制。此外,他们承诺以个性化的方式,即通过使用患者来源的肿瘤材料进行此类测试,提供推定的抗肿瘤药物和替代治疗方法的筛选。然而,为了变得可靠和具有代表性,神经胶质瘤模型系统需要包括大多数固有的癌症特征,如局部缺氧、特异性遗传畸变、原生肿瘤微环境和三维细胞外基质。本文首先简要介绍了胶质瘤的一般流行病学和分子特征,然后概述了目前用于胶质瘤研究的基于细胞的体外模型。作为结论,我们建议采用创新的基于细胞的体外神经胶质瘤模型。我们认为,选择这些方法的主要标准应包括与体内关键特征的足够相似性、稳健性、成本效益和易用性,以及高通量处理的适应性,以实现标准化药物筛选。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
AIMS Genetics
AIMS Genetics GENETICS & HEREDITY-
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊最新文献
Evidence for novel epigenetic marks within plants. The roles of genes in the bitter taste. A robust circular RNA-based prognostic signature for postoperative recurrence in stage II/III colon cancer. Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety PDE4B gene polymorphism in Russian patients with panic disorder
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1